Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11905011 | 0.88 | KCNH2 (0.40) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL6888796 | 0.82 | KCNH2 (0.42) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL6886624 | 0.81 | MAPT (0.39) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL1668496 | 0.80 | CCR2 (0.39) | KCNH2 | |
| SCHEMBL1670054 | 0.79 | KCNH2 (0.45) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL6887526 | 0.79 | KCNH2 (0.40) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL6889065 | 0.79 | KCNH2 (0.41) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL1670851 | 0.78 | KCNH2 (0.38) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL2461130 | 0.77 | IP6K1 (0.40) | CNR1CNR2HPGDSNPC1 | |
| SCHEMBL6887891 | 0.77 | BMPR1B (0.43) | KCNH2CHRNA7CHRNA1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | CNR1 904/4885CNR2 705/4885KCNH2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.